Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

NCT04478695 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Amgen Decision

Conditions

Relapsed or Refractory Acute Myeloid Leukemia

Interventions

DRUG: AMG 330
DRUG: Pembrolizumab

Sponsor

Amgen

Collaborators

[object Object]